In the rapidly evolving field of neurotechnology, China is positioning itself as a formidable contender against Elon Musk's Neuralink. Last year, in 2025, brain-computer interfaces (BCIs) were elevated to a national strategic sector in China, with the government launching an ambitious program featuring streamlined regulations, accelerated funding, and coordinated resource allocation.
This initiative has already spurred over 10 ongoing invasive human trials, aiming to cultivate 2-3 world-class companies by 2030. As of February 2026, this push is yielding tangible results, with Chinese startups like NeuroXess accelerating their progress and challenging Western dominance.
China's National Strategy for BCI Dominance
China's commitment to BCIs is rooted in a comprehensive roadmap outlined in the "Implementation Opinions on Promoting the Innovative Development of the Brain-Computer Interface Industry," jointly issued by seven key ministries in August 2025.
This policy targets major technical breakthroughs by 2027, including advancements in chips, software, and standards, while fostering a complete supply chain by 2030. The sector's market value, which stood at 3.2 billion yuan (about $446 million) in 2024, is projected to reach 5.58 billion yuan by 2027, reflecting a 20% annual growth rate.
Provinces like Shanghai are leading the charge. In January 2025, Shanghai released its own BCI Future Industry Development Action Plan (2025–2030), focusing on high-quality brain-control capabilities, leadership in semi-invasive BCIs, and breakthroughs in invasive technologies by 2027. This regional and national synergy includes an 11.6 billion yuan ($165 million) brain science fund announced at the 2025 Shenzhen BCI Expo, designed to propel companies from research to commercialization. Such efforts are part of China's broader 15th Five-Year Plan (2026-2030), which identifies BCIs as one of six priority future industries.
NeuroXess: A Key Contender in the Race
At the forefront of China's BCI surge is Shanghai-based startup NeuroXess, founded in 2021. In just four years, the company has conducted over 50 implantations of neural chips — far surpassing Neuralink's reported trials. NeuroXess recently achieved a milestone by implanting China's first fully implantable BCI with a built-in battery, making it only the second company worldwide after Neuralink to do so.
The design of NeuroXess's device emphasizes safety and integration. The entire main unit is internalized, with the battery placed subcutaneously in the chest area, enabling wireless power and data transmission without any external equipment.
This eliminates infection risks associated with external connections. Heat-generating components are positioned away from the brain to enhance safety.
Technologically, NeuroXess employs a polyimide mesh placed on the brain's surface, avoiding penetration into brain tissue — unlike Neuralink's microscopic threads that embed within the tissue. This surface-based approach mitigates concerns about tissue scarring around electrodes.
In terms of performance, Neuralink currently leads with a bandwidth of 10 bits per second, compared to NeuroXess's 5.2 bits per second. However, NeuroXess has demonstrated real-world efficacy: A paralyzed patient controlled a computer cursor within five days of implantation. The company's ECoG (electrocorticography) system, featuring a flexible high-density electrode array with 256 electrodes, has shown promising results in decoding Mandarin syllables with 71.2% accuracy and real-time sentence decoding at 49.7 characters per minute.
Technological Paths and Future Prospects
NeuroXess and Neuralink represent divergent approaches in BCI development. Neuralink's invasive method offers higher resolution but raises long-term safety questions, while NeuroXess's less invasive surface placement prioritizes biocompatibility and reduced risks. Looking ahead, NeuroXess plans to register clinical trials this year and move toward commercialization, with construction underway on a "super factory" for mass production starting in the second half of 2026.
China's broader ecosystem includes other players like BrainCo, Neuracle, and Gestala, spanning invasive and noninvasive technologies. With streamlined approvals and increased funding, these efforts are accelerating the transition from lab to market, potentially outpacing Neuralink in scale and accessibility.
Also read:
- QUASA: The world’s first and only Web3 mobile app for 0% fee crypto freelancing
- Perplexity Pivots Mid-Air: From Google Killer to Niche Professional Service
- How Gold Sellers Make Money (And Why Marketing Is Everything)
- Apple and Netflix Abandon Premium Games: Subscription Model Falls Short
Conclusion
As China invests heavily in BCIs, the global landscape of neurotechnology is shifting. By fostering innovation through policy support and rapid trials, companies like NeuroXess are not just challenging Neuralink but redefining the future of human-machine integration. With ethical guidelines in place and a focus on applications in healthcare, industry, and consumer sectors, China's strategy could lead to breakthroughs that benefit humanity worldwide.
